


Docket No.: PF-0556-1 DIV

0590
1029

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on November 21, 2001.

By: 
Printed: Katherine Stofer

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Tang et al.

Title: THIOREDOXIN PROTEINS

Serial No.: 09/954,846 Filing Date: September 17, 2001

Examiner: To be assigned Group Art Unit: To be assigned

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT WITH FEE UNDER §1.17(p)

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the Supplemental List of References Cited by Applicants be returned to Applicants.

The cited PCT applications are listed below. The PCT applications comprise the indicated number of pages, and where known, the SEQ ID NO: of the sequence which is believed to be of interest in examination of the instant application is indicated.

<u>PCT Application</u>	<u>No. Pages</u>	<u>SEQ ID NO: of interest</u>
WO 99/18204	84	12
WO 98/46756	138	2
WO 98/07749	141	4
WO 99/09061	75	13

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for any reason the Examiner considers otherwise, please telephone the undersigned.


Please charge Deposit Account No. **09-0108** the **\$180.00** processing fee for the Information Disclosure Statement under 37 C.F.R. §1.17(p). **A duplicate copy of this communication is enclosed.** The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 09-0108.

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: December 21, 2001


David G. Streeter, Ph.D.
Reg. No. 43,168
Direct Dial Telephone: (650) 845-5741

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166